{rfName}
Ev

Indexed in

License and use

Icono OpenAccess

Citations

5

Altmetrics

Article has an altmetric score of 13

Analysis of institutional authors

Marco-Brualla, JoaquinAuthor

Share

Publications
>
Article

Evaluation in a Cytokine Storm Model In Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells)

Publicated to:Biomedicines. 10 (5): 1094- - 2022-05-01 10(5), DOI: 10.3390/biomedicines10051094

Authors: Pedro Lapuente, Juan; Gomez, Gonzalo; Marco-Brualla, Joaquin; Fernandez, Pablo; Desportes, Paula; Sanz, Jara; Garcia-Gil, Mario; Bermejo, Fernando; Victor San Martin, Juan; Algaba, Alicia; Carlos De Gregorio, Juan; Lapuente, Daniel; De Gregorio, Almudena; Lapuente, Belen; Gomez, Sergio; de las Vinas Andres, Maria; Anel, Alberto

Affiliations

Fuelabrada Hosp, Clin Assay Dept, Madrid 28942, Spain - Author
Fuenlabrada Hosp, Digest Dept, Madrid 28942, Spain - Author
Fuenlabrada Hosp, Internal Med Dept, Madrid 28942, Spain - Author
Fuenlabrada Hosp, Mol & Cell Biol Res Labs R4T, Madrid 28942, Spain - Author
Fuenlabrada Hosp, Pharm Dept, Madrid 28942, Spain - Author
Peaches Biotech, GMP Facil, Madrid 28050, Spain - Author
Univ Rey Juan Carlos, Med Dept, Madrid 28942, Spain - Author
Univ Zaragoza, Grp Immun Canc & Stem Cells, Fac Sci, E-50009 Zaragoza, Spain - Author
See more

Abstract

Keywords

CocultureCrosstalkCytokine stormDifferentiationInfectioInflammatioInflammationKappa-bM2 macrophagesMacrophage activationMesenchymal stem cellsMetalloproteinasesMortalityPrognosisPrs ck stormSecretomeSepsisTissue inhibitorsToll-like receptors

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Biomedicines due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 68/278, thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology & Pharmacy.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-06-27:

  • WoS: 2
  • Scopus: 2
  • Europe PMC: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-27:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 16.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 16 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 12.1.
  • The number of mentions on the social network X (formerly Twitter): 5 (Altmetric).
  • The number of mentions in news outlets: 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.